论文部分内容阅读
Complicated intra-abdominal infections,hospital-acquired pneumonia including ventilator-associated pneumonia,complicated urinary tract infections and staphylococcal infections continue to play a significant role in the overall morbidity and mortality of intensive care patients.However,increasing resistance of multiple pathogenic bacteria,responsible for life-threatening infections,to commonly used antibiotic groups is a continuing challenge to critical care physicians.In an ongoing search for treatment of these infections,several promising antibacterial agents have been investigated in recent clinical trials.A new beta-lactam antibiotic of the carbapenem group,doripenem,is a synthetic 1-beta-methyl carbapenem with stability against several beta-lactamases and dehydropeptidase-1.It has been shown to have in-vitro activity against a wide group of aerobic and anaerobic gram-positive and gram-negative bacteria.Based on minimum inhibitory concentration (MIC),doripenem is the most potent carbapenem against Psudomonas aeruginosa isolates.It has been approved for the treatment of severe intra-abdominal infections and complicated urinary tract infections.Recent Phase Ⅲ clinical studies have also confirmed its efficacy in the treatment of ventilator-associated pneumonia.Biopenem,another carbapenem with broad bactericidal activity,is currently undergoing Phase Ⅱ clinical trials in USA.Ceftobiprole,the active cephalosporin of the pro-drug ceftobiprole medocaril,is a broad-spectrum antibiotic with anti-methicillin resistant staphylococcus aureus (MRSA) activity.